Posted by Michael Wonder on 17 Mar 2022
Evusheld approved to prevent COVID-19 in people whose immune response is poor
17 March 2022 - The decision to grant approval for this treatment was endorsed by the Government’s independent expert scientific advisory body, the Commission on Human Medicines, after carefully reviewing the evidence.
A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the MHRA after meeting the UK regulatory standards of safety, quality and effectiveness.
